The invention relates generally to medical devices. More specifically, the invention relates to a physiological monitoring device and method for use.
Abnormal heart rhythms, or arrhythmias, may cause various types of symptoms, such as loss of-consciousness, palpitations, dizziness, or even death. An arrhythmia that causes such symptoms is often an indicator of significant underlying heart disease. It is important to identify when such symptoms are due to an abnormal heart rhythm, since treatment with various procedures, such as pacemaker implantation or percutaneous catheter ablation, can successfully ameliorate these problems and prevent significant symptoms and death.
Since the symptoms listed above can often be due to other, less serious causes, a key challenge is to determine when any of these symptoms are due to an arrhythmia. Oftentimes, arrhythmias occur infrequently and/or episodically, making rapid and reliable diagnosis difficult. Currently, cardiac rhythm monitoring is primarily accomplished through the use of devices, such as Holter monitors, that use short-duration (<1 day) electrodes affixed to the chest. Wires connect the electrodes to a recording device, usually worn on a belt. The electrodes need daily changing and the wires are cumbersome. The devices also have limited memory and recording time. Wearing the device interferes with patient movement and often precludes performing certain activities while being monitored, such as bathing. All of these limitations severely hinder the diagnostic usefulness of the device, the compliance of patients using the device and the likelihood of capturing all important information. Lack of compliance and the shortcomings of the devices often lead to the need for additional devices, follow-on monitoring or other tests to make a correct diagnosis.
Current methods to correlate symptoms with the occurrence of arrhythmias, including the use of cardiac rhythm monitoring devices, such as Holter monitors and cardiac event recorders, are often not sufficient to allow an accurate diagnosis to be made. In fact, Holter monitors have been shown to not lead to a diagnosis up to 90% of the time (“Assessment of the Diagnostic Value of 24-Hour Ambulatory Electrocariographic Monitoring”, by DE Ward et al. Biotelemetry Patient Monitoring, vol. 7, published in 1980).
Additionally, the medical treatment process to actually obtain a cardiac rhythm monitoring device and initiate monitoring is typically very complicated. There are usually numerous steps involved in ordering, tracking, monitoring, retrieving, and analyzing the data from such a monitoring device. In most cases, cardiac monitoring devices used today are ordered by a cardiologist or a cardiac electrophysiologist (EP), rather than the patient's primary care physician (PCP). This is of significance since the PCP is often the first physician to see the patient and determine that the patient's symptoms could be due to an arrhythmia. After the patient sees the PCP, the PCP will make an appointment for the patient to see a cardiologist or an EP. This appointment is usually several weeks from the initial visit with the PCP, which in itself leads to a delay in making a potential diagnosis as well as increases the likelihood that an arrhythmia episode will occur and go undiagnosed. When the patient finally sees the cardiologist or EP, a cardiac rhythm monitoring device will usually be ordered. The monitoring period can last 24-48 hours (Holter monitor) or up to a month (cardiac event monitor or mobile telemetry device). Once the monitoring has been completed, the patient typically must return the device to the clinic, which itself can be an inconvenience. After the data has been processed by the monitoring company or by a technician on-site at a hospital or office, a report will finally be sent to the cardiologist or EP for analysis. This complex process results in fewer patients receiving cardiac rhythm monitoring than would ideally receive it.
To address some of these issues with cardiac monitoring, the assignee of the present application developed various embodiments of a small, long-term, wearable, physiological monitoring device. One embodiment of the device is the Zio® Patch (www.irhythmtech.com). Various embodiments are also described, for example, in U.S. Pat. Nos. 8,150,502, 8,160,682 8,244,335, 8,560,046, and 8,538,503, the full disclosures of which are hereby incorporated by reference. Generally, the physiological monitors described in the above references fit comfortably on a patient's chest and are designed to be worn for at least one week and typically two to three weeks. The monitors detect and record cardiac rhythm signal data continuously while the device is worn, and this cardiac rhythm data is then available for processing and analysis.
These smaller, long-term physiological monitoring devices provided many advantages over prior art devices. At the same time, further improvements are desired. One of the most meaningful areas for improvement exists around increasing fidelity of the recorded ECG signal. This is particularly important for single-channel embodiments where a second vector of ECG is not available to clarify whether aberrances in signal are due to arrhythmia or signal artifact. Increases in signal to noise ratio as well as reduction of motion artifact improve efficiency in both algorithmic and human analysis of the recorded ECG signal.
Signal quality is important throughout the duration of wear, but it is particularly critical where the patient marks the record, indicating an area of symptomatic clinical significance. Marking the record is most easily enabled through a trigger located on the external surface of the device. However, since the trigger is part of a skin-contacting platform with integrated electrodes, the patient can introduce significant motion artifacts when feeling for the trigger. A desirable device improvement would be a symptom trigger that can be activated with minimal addition of motion artifact.
Secondly, patient compliance and device adhesion performance are two factors that govern the duration of the ECG record and consequently the diagnostic yield. Compliance can be increased by improving the patient's wear experience, which is affected by wear comfort, device appearance and the extent to which the device impedes the normal activities of daily living. Given that longer ECG records provide greater diagnostic yield and hence value, improvements to device adhesion and patient compliance are desirable.
Finally, it is desirable for the device to be simple and cost effective to manufacture, enabling scalability at manufacturing as well as higher quality due to repeatability in process. Simplicity of manufacture can also lead to ease of disassembly, which enables the efficient recovery of the printed circuit board for quality-controlled reuse in another device. Efficient reuse of this expensive component is critical for decreasing the cost of the diagnostic monitor. At least some of the objectives will be met by the embodiments described below.
Embodiments described herein are directed to a physiological monitoring device that may be worn continuously and comfortably by a human or animal subject for at least one week or more and more typically two to three weeks or more. In one embodiment, the device is specifically designed to sense and record cardiac rhythm (i.e., electrocardiogram, ECG) data, although in various alternative embodiments one or more additional physiological parameters may be sensed and recorded. The physiological monitoring device includes a number of features to facilitate and/or enhance the patient experience, to make diagnosis of cardiac arrhythmias more accurate, and to make manufacture of the device more simple and cost effective.
In some embodiments, an electronic device for monitoring physiological signals in a mammal comprises:
In certain embodiments, each wing may comprise an adhesive. In embodiments, the electrodes can be in the same plane as the adhesive. In certain embodiments, each wing comprises at least one rim, wherein the rim is thinner than an adjacent portion of each wing. The rigid housing may further comprise dimples configured to allow for airflow between the rigid housing and the surface of the mammal. In certain embodiments, the rim is configured to prevent the release of a portion of the wing from the surface of the mammal. In some embodiments, an electronic device for monitoring physiological systems may comprise a measuring instrument configured to detect motion signals in at least one axis. This measuring instrument may be an accelerometer that can be configured to detect motion signals in three axes.
In embodiments, the motion signals can be collected in time with the physiological signals. In certain embodiments, a motion artifact is identified when the physiological signals and the motion signals match. Further embodiments may call for an event trigger coupled to the printed circuit board assembly. In some embodiments, the event trigger input is supported by the rigid housing so as to prevent mechanical stress on the printed circuit board when the trigger is activated. The event trigger may be concave and larger than a human finger such that the event trigger is easily located. In certain embodiments, the electrode traces are configured to minimize signal distortion during movement of the mammal. In particular embodiments, gaskets may be used as a means for sealable attachment to the rigid housing.
In certain embodiments, a method for monitoring physiological signals in a mammal may comprise:
In certain embodiments, identification of an artifact comprises a comparison between the frequency spectrum of the physiological signals and the frequency spectrum of the secondary signals. In embodiments, the secondary signals comprise motion signals that may be used to derive the activity and position of the mammal. In certain embodiments, the secondary signals are collected in three axes. In some embodiments, a tertiary signal may also be collected. In certain embodiments, the secondary signals comprise information about the connection between the electronic device and the mammal. In some embodiments, the secondary signals may be used to detect when the mammal is sleeping.
In some embodiments, a method of removing and replacing portions of a modular physiological monitoring device may comprise
In some embodiments, the first component is electrically connected to other device components without the use of a permanent connection. In some embodiments, the device may further comprise spring connections. In certain embodiments, the first component may be preserved for a second use by a rigid housing to prevent damage. In particular embodiments, the first component is secured within a device by a mechanism that is capable of re-securing a second component once the first component is removed.
These and other aspects and embodiments of the invention are described in greater detail below, with reference to the drawing figures.
The following description is directed to a number of various embodiments. The described embodiments, however, may be implemented and/or varied in many different ways without departing from the scope of the invention. For example, the described embodiments may be implemented in any suitable device, apparatus, or system to monitor any of a number of physiological parameters. For example, the following discussion focuses primarily on long-term, patch-based cardiac rhythm monitoring devices. In one alternative embodiment, a physiological monitoring device may be used, for example, for pulse oximetry and diagnosis of obstructive sleep apnea. In various alternative embodiments, one size of physiological monitor may be used for adult patients and another size may be used for pediatric patients. The method of using a physiological monitoring device may also vary. In some cases, a device may be worn for one week or less, while in other cases, a device may be worn for at least seven days and/or for more than seven days, for example between fourteen days and twenty-one days or even longer. Many other alternative embodiments and applications of the described technology are possible. Thus, the following description is provided for exemplary purposes only. Throughout the specification, reference may be made to the term “conformal.” It will be understood by one of skill in the art that the term “conformal” as used herein refers to a relationship between surfaces or structures where a first surface or structure fully adapts to the contours of a second surface or structure.
Referring to
As will be explained in further detail below, the combination of a highly flexible body 110, including flexible electrodes and electrode traces 311, 312, with a very rigid housing 115 may provide a number of advantages. For example, flexible body 110 includes a configuration and various features that facilitate comfortable wearing of device 100 by a patient for fourteen (14) days or more without removal. Rigid housing 115, which typically does not adhere to the patient in the embodiments described herein, includes features that lend to the comfort of device 100. Rigid housing 115 also protects the electronics and power source contained in housing 120, enhances the ability of a patient to provide an input related to a perceived cardiac event, and allows for simple manufacturing and reusability of at least some of the contents of housing 115. These and other features of physiological monitoring device 100 are described in greater detail below.
Referring now to
Battery holder 150, according to various alternative embodiments, may hold two batteries (as in the illustrated embodiment), one battery, or more than two batteries. In other alternative embodiments, other power sources may be used. In the embodiment shown, battery holder 150 includes multiple retain tabs 153 for holding batteries 160 in holder 150. Additionally, battery holder 150 includes multiple feet 152 to establish correct spacing of batteries 160 from the surface of PCBA 120 and ensure proper contact with spring fingers 235 and 236. Spring fingers 235 and 236 are used in this embodiment rather than soldering batteries 160 to PCBA 120. Although soldering may be used in alternative embodiments, one advantage of spring fingers 235 and 236 is that they allow batteries 160 to be removed from PCBA 120 and holder 150 without damaging either of those components, thus allowing for multiple reuses of both. Eliminating solder connections also simplifies and speeds up assembly and disassembly of monitoring device 100.
In some embodiments, upper housing member 140 may act as a patient event trigger. When a patient is wearing physiological monitoring device 100 for cardiac rhythm monitoring, it is typically advantageous for the patient to be able to register with device 100 (i.e., log into the device's memory) any cardiac events perceived by the patient. If the patient feels what he/she believes to be an episode of heart arrhythmia, for example, the patient may somehow trigger device 100 and thus provide a record of the perceived event. At some later time, the patient's recorded perceived event could be compared with the patient's actual heart rhythm, recorded by device 100, and this may help determine whether the patient's perceived events correlate with actual cardiac events. One problem with patient event triggers in currently available wearable cardiac rhythm monitoring devices, however, is that a small trigger may be hard to find and/or activate, especially since the monitoring device is typically worn under clothing. Additionally, pressing a trigger button may affect the electronics and/or the electrodes on the device in such a way that the recorded heart rhythm signal at that moment is altered simply by the motion caused to the device by the patient triggering. For example, pressing a trigger may jar one or both of the electrodes in such a way that the recorded heart rhythm signal at that moment appears like an arrhythmia, even if no actual arrhythmia event occurred. Additionally, there is a chance that the trigger may be inadvertently activated, for instance while sleeping or laying on the monitoring device.
In the embodiment shown in
Referring now to
Patient trigger input 210 may be configured to relay a signal from a patient trigger, such as upper housing member 140 described above, to PCBA 120. For example, patient trigger input 210 may be a PCB switch or button that is responsive to pressure from the patient trigger (i.e., the upper surface of upper housing portion 140). In various embodiments, patient trigger input 210 may be a surface mounted switch, a tactile switch, an LED illuminated tactile switch, or the like. In some embodiments, patient trigger input 210 may also activate an indicator, such as an LED.
One important challenge in collecting heart rhythm signals from a human or animal subject with a small, two-electrode physiological monitoring device such as device 100 described herein, is that having only two electrodes can sometimes provide a limited perspective when trying to discriminate between artifact and clinically significant signals. For example, when a left-handed patient brushes her teeth while wearing a small, two-electrode physiological monitoring device on her left chest, the tooth brushing may often introduce motion artifact that causes a recorded signal to appear very similar to Ventricular Tachycardia, a serious heart arrhythmia. Adding additional leads (and, hence, vectors) is the traditional approach toward mitigating this concern, but this is typically done by adding extra wires adhered to the patient's chest in various locations, such as with a Holter monitor. This approach is not consistent with a small, wearable, long term monitor such as physiological monitoring device 100.
An alternate approach to the problem described above is to provide one or more additional data channels to aid signal discrimination. In some embodiments, for example, device 100 may include a data channel for detecting patch motion. In certain embodiments, an accelerometer may provide patch motion by simply analyzing the change in magnitude of a single axis measurement, or alternatively of the combination of all three axes. The accelerometer may record device motion at a sufficient sampling rate to allow algorithmic comparison of its frequency spectrum with that of the recorded ECG signal. If there is a match between the motion and recorded signal, it is clear that the device recording in that time period is not from a clinical (e.g., cardiac) source, and thus that portion of the signal can be confidently marked as artifact. This technique may be particularly useful in the tooth brushing motion example aforementioned, where the rapid frequency of motion as well as the high amplitude artifact is similar to the heart rate and morphology, respectively, of a potentially life-threatening arrhythmia like Ventricular Tachycardia.
In some embodiments, using the magnitude of all three axes for such an analysis would smooth out any sudden changes in values due to a shift in position rather than a change in activity. In other embodiments, there may be some advantage in using a specific axis of measurement such as along the longitudinal axis of the body to focus on a specific type of artifact introduced by upward and downward movements associated with walking or running. In a similar vein, the use of a gyroscope in conjunction with the accelerometer may provide further resolution as to the nature of the motion experienced. While whole body movements may be sufficiently analyzed with an accelerometer on its own, specific motion of interest such as rotational motion due to arm movement is sufficiently complex that an accelerometer alone might not be able to distinguish.
In addition to detecting motion artifact, an accelerometer tuned to the dynamic range of human physical activities may provide activity levels of the patient during the recording, which can also enhance accuracy of algorithmic true arrhythmia detection. Given the single-lead limitation of device 100, arrhythmias that require observation of less prominent waves (e.g. P-wave) in addition to rate changes such as Supraventricular Tachycardia pose challenges to both computerized algorithms as well as the trained human eye. This particular arrhythmia is also characterized by the sudden nature of its onset, which may be more confidently discriminated from a non-pathological Sinus Tachycardia if a sudden surge in the patient's activity level is detected at the same time as the increase in heart rate. Broadly speaking, the provision of activity information to clinical professionals may help them discriminate between exercise-induced arrhythmia versus not. As with motion artifact detection, a single-axis accelerometer measurement optimized to a particular orientation may aid in more specifically determining the activity type such as walking or running. This additional information may help explain symptoms more specifically and thereby affect the subsequent course of therapeutic action.
In certain embodiments, an accelerometer with 3 axes may confer advantages beyond what magnitude of motions can provide. When the subject is not rapidly moving, 3-dimensional accelerometer readings may approximate the tilt of PCBA 120, and therefore body orientation relative to its original orientation. The original body orientation can be assumed to be in either an upright or supine position which is required for appropriate positioning and application of the device to the body. This information may aid in ruling out certain cardiac conditions that manifest as beat-to-beat morphology changes, such as cardiac alternans where periodic amplitude changes are observed, often in heart failure cases. Similar beat-to-beat morphology changes are observable in healthy subjects upon shift in body position due to the shift in heart position relative to the electrode vector, for example from an upright to a slouching position. By design, the single-channel device 100 does not have an alternate ECG channel to easily rule out potential pathological shifts in morphology, however, correlation with shifts in body orientation will help explain these normal changes and avoid unnecessary treatment due to false diagnosis.
In other embodiments, the accelerometer may also be used as a sleep indicator, based on body orientation and movement. When presenting clinical events (e.g., pauses), it is diagnostically helpful to be able to present information in a manner that clearly separates events that occurred during sleep from those during waking hours. In fact, certain algorithms such as for ECG-derived respiratory rate only make sense to run when the patient is in a relatively motionless state and therefore subtle signal modulation introduced by chest movement due to breathing is observable. Respiratory rate information is useful as one channel of information necessary to detect sleep apnea in certain patient populations.
In certain embodiments, the accelerometer may also be used to detect free-falls, such as fainting. With an accelerometer, device 100 may be able to mark fainting (syncope) and other free-fall events without relying on patient trigger. In order to allow timely detection of such critical events, yet considering the battery and memory limitations of a small, wearable device such as device 100, acquisition of accelerometer readings may be done in bursts, where only interesting information such as a potential free fall is written to memory at a high sampling rate. An expansion of this event-trigger concept is to use specific tapping motions on device 100 as a patient trigger instead of or in conjunction with the button previously described. The use and detection of multiple types of tapping sequences may provide better resolution and accuracy into what exactly the patient was feeling, instead of relying on the patient to manually record their symptom and duration in a trigger log after the fact. An example of such added resolution is to indicate the severity of the symptom by the number of sequential taps.
Alternatively, in other embodiments, an optical sensors may be used to distinguish between device motion and patient body motion. Further, in additional embodiments, the device may not require a button or trigger.
Another optional data channel that may be added to physiological monitoring device 100 is a channel for detecting flex and/or bend of device 100. In various embodiments, for example, device 100 may include a strain gauge, piezoelectric sensor or optical sensor to detect motion artifact in device 100 itself and thus help to distinguish between motion artifact and cardiac rhythm data. Yet another optional data channel for device 100 may be a channel for detecting heart rate. For example, a pulse oximeter, microphone or stethoscope may provide heart rate information. Redundant heart rate data may facilitate discrimination of ECG signals from artifact. This is particularly useful in cases where arrhythmia such as Supraventricular Tachycardia is interrupted by artifact, and decisions must be made whether the episode was actually multiple shorter episodes or one sustained episode. Another data channel may be included for detecting ambient electrical noise. For example, device 100 may include an antenna for picking up electromagnetic interference. Detection of electromagnetic interference may facilitate discrimination of electrical noise from real ECG signals. Any of the above-described data channels may be stored to support future noise discrimination or applied for immediate determination of clinical validity in real-time.
With reference now to
Hinge portions 132 are relatively thin, even more flexible portions of flexible body 110. They allow flexible body 110 to flex freely at the area where it is joined to rigid housing 115. This enhances comfort, since when the patient moves, housing 115 can freely lift off of the patient's skin. Electrode traces 311, 312 are also very thin and flexible, to allow for patient movement without signal distortion. Borders 133 are portions of flexible body 110 that is thinner than immediately adjacent portions and that provide for a smooth transition from flexible body 110 to a patient's skin, thus preventing edge-lift and penetration of dirt or debris below flexible body 110.
As shown in greater detail in
Typically, top and bottom substrate layers 300, 330 are attached to one another via adhesive placed on one or both layers 300, 330. For example, the adhesive or bonding substance between substrate layers 300, 330 may be an acrylic-based, rubber-based, or silicone-based adhesive. In other alternative embodiments, flexible body 110 may include more than two layers of flexible material.
In addition to the choice of material(s), the dimensions—thickness, length and width—of substrate layers 300, 330 may be selected based on desired characteristics of flexible body 110. For example, in various embodiments, the thickness of substrate layers 300, 330 may be selected to give flexible body 110 an overall thickness of between about 0.1 mm to about 1.0 mm. According to various embodiments, flexible body 110 may also have a length of between about 7 cm and 15 cm and a width of about 3 cm and about 6 cm. Generally, flexible body 110 will have a length sufficient to provide a necessary amount of separation between electrodes 350. For example, a distance from the center of one electrode 350 to the center of the other electrode 350 should be at least about 6.0 cm and more preferably at least about 8.5 cm. This separation distance may vary, depending on the application. In some embodiments, substrate layers 300, 330 may all have the same thickness. Alternatively, the two substrate layers 300, 330 may have different thicknesses.
As mentioned above, hinge portions 132 allow the rigid body 115 to lift away from the patient while flexible body 110 remains adhered to the skin. The functionality of hinge portions 132 is critical in allowing the device to remain adhered to the patient throughout various activities that may stretch and compress the skin. Furthermore, hinge portions 132 allow for significantly improved comfort while wearing the device. Generally, hinge portions 132 will be sufficiently wide enough to provide adequate lift of rigid body 115 without creating too large of a peel force on flexible body 110. For example, in various embodiments, the width of hinge portion 132 should be at least about 0.25 cm and more preferably at least about 0.75 cm.
Additionally, the shape or footprint of flexible body 110 may be selected based on desired characteristics. As seen in
While the illustrated embodiments of
Adhesive layer 340 is an adhesive that is applied to two portions of the bottom surface of bottom substrate layer 330, each portion corresponding to one of wings 130, 131. Adhesive layer 340 thus does not extend along the portion of bottom substrate layer 330 upon which rigid housing 115 is mounted. Adhesive layer 340 may be made of any suitable adhesive, although certain adhesives have been found to be advantageous for providing long term adhesion to patient skin with relative comfort and lack of skin irritation. For example, in one embodiment, adhesive layer 340 is a hydrocolloid adhesive. In another embodiment, the adhesive layer 340 is comprised of a hydrocolloid adhesive that contains naturally-derived or synthetic absorbent materials which take up moisture from the skin during perspiration.
Each of the two portions of adhesive layer 340 includes a hole, into which one of electrodes 350 fits. Electrodes 350 made of flexible material to further provide for overall conformability of flexible body 110. In one embodiment, for example, flexible electrodes 350 may be made of a hydrogel 350. Electrodes 350 generally provide conformal, non-irritating contact with the skin to provide enhanced electrical connection with the skin and reduce motion artifact. In some embodiments, hydrogel electrodes 350 may be punched into adhesive layer 340, thus forming the holes and filling them with hydrogel electrodes 350. In one alternative embodiment, electrodes 350 and adhesive 340 may be replaced with an adhesive layer made of a conductive material, such that the entire adhesive layer on the underside of each wing 130, 131 acts as an electrode. Such an adhesive layer may include a hybrid adhesive/conductive substance or adhesive substance mixed with conductive elements or particles. For example, in one embodiment, such an adhesive layer may be a hybrid of a hydrogel and a hydrocolloid adhesive.
As discussed above, in some embodiments, adhesive layer 340 may cover a portion of the underside of lower substrate layer 330, such that at least a portion of the bottom side of flexible body 110 does not include adhesive layer 340. As seen in
Flexible body 110 further includes two electrode traces 311, 312 sandwiched between upper substrate layer 300 and lower substrate layer 330. Each electrode trace 311, 312 may include an electrode interface portion 310 and an electrocardiogram circuit interface portion 313. As illustrated in
The material and thickness of electrode traces 311, 312 are important for providing a desired combination of flexibility, durability and signal transmission. For example, in one embodiment, electrode traces 311, 312 may include a combination of silver (Ag) and silver chloride (AgCl). The silver and silver chloride may be disposed in layers. For example, one embodiment of electrode traces 311, 312 may include a top layer of silver, a middle layer of carbon impregnated vinyl, and a bottom (patient-facing) layer of silver chloride. In another embodiment, both top and bottom layers of electrode traces 311, 312 may be made of silver chloride. In one embodiment, the top and bottom layers may be applied to the middle layer in the form of silver ink and silver chloride ink, respectively. In an alternative embodiment, each electrode trace may include only two layers, such as a top layer of silver and a bottom layer of silver chloride. In various embodiments, the material of a bottom layer of each electrode trace 311, 312, such as AgCl, may be selected to match the chemistry of the hydrogel electrodes 350 and create a half-cell with the body of the subject.
The thickness of the electrode traces 311, 312 may be selected to optimize any of a number of desirable properties. For example, in some embodiments, at least one of the layers of electrode traces 311, 312 can be of a sufficient thickness to minimize or slow depletion of the material from an anode/cathode effect over time. Additionally, the thickness may be selected for a desired flexibility, durability and/or signal transmission quality. Flexible electrode traces 311, 312 generally may help provide conformal contact with the subject's skin and may help prevent electrodes 350 from peeling or lifting off of the skin, thereby providing strong motion artifact rejection and better signal quality by minimizing transfer of stress to electrodes 350.
As mentioned above, in some embodiments, top gasket 370 and bottom gasket 360 may be attached upper substrate 300 and lower substrate 330 of flexible body 110. Gaskets 360, 370 may be made of any suitable material, such as urethane, which provides a water tight seal between the upper housing member 140 and lower housing member 145 of rigid housing 115. In one embodiment, top gasket 370 and/or bottom gasket 360 may include an adhesive surface.
With reference now to
With continued reference to
Referring now to
With reference now to
It is desirable that PCBA 120 is sufficiently rigid to prevent bending and introducing unwanted artifact into the signal. In certain embodiments, an additional mechanism to reduce and prevent unwanted bending of PCBA 120 may be used. This mechanism is shown in
Referring to
Labels 820, 840 may be any suitable labels and may include produce name(s), manufacturer name(s), logo(s), design(s) and/or the like. They may be removable or permanently attached upper housing member 140 and/or lower housing member 145, although typically they will be permanently attached, to avoid unregulated reuse and/or resale of the device by an unregistered user. Device identifier 830 may be a barcode sticker, computer readable chip, RFID, or the like. Device identifier 830 may be permanently or removably attached to PCBA 120, flexible body 110 or the like. In some embodiments, it may be beneficial to have device identifier 830 stay with PCBA 120.
Referring now to
Referring now to
In a next step, referring to
When a desired monitoring period has ended, such as about 14-21 days in some cases, a patient (or physician, nurse or the like) may remove physiological monitoring device 100 from the patient's skin, place device 100 in a prepaid mailing pouch, and mail device 100 to a data processing facility. At this facility, device 100 may be partially or completely disassembled, PCBA 120 may be removed, and stored physiological data, such as continuous heart rhythm information, may be downloaded from PCBA 120. The data may then be analyzed by any suitable method and then provided to a physician in the form of a report. The physician may then discuss the report with the patient. PCBA 120 and/or other portions of device 100, such as rigid housing 115, may be reused in the manufacture of subsequent devices for the same or other patients. Because device 100 is built up as a combination of several removably coupled parts, various parts may be reused for the same embodiment or different embodiments of device 100. For example, PCBA 120 may be used first in an adult cardiac rhythm monitor and then may be used a second time to construct a monitor for sleep apnea. The same PCBA 120 may additionally or alternatively be used with a differently sized flexible body 110 to construct a pediatric cardiac monitor. Thus, at least some of the component parts of device 100 may be interchangeable and reusable.
Advantageously, physiological monitoring device 100 may provide long term adhesion to the skin. The combination of the configuration of flexible and conformal body 110, the watertight, low profile configuration of rigid housing 115, and the interface between the two allows device 100 to compensate for stress caused as the skin of the subject stretches and bends. As a result, device 100 may be worn continuously, without removal, on a patient for as many as 14-21 days or more. In some cases, device 100 may be worn for greater or less time, but 14-21 days may often be a desirable amount of time for collecting heart rhythm data and/or other physiological signal data from a patient.
In various alternative embodiments, the shape of a particular physiological monitoring device may vary. The shape, footprint, perimeter or boundary of the device may be circular, an oval, triangular, a compound curve or the like, for example. In some embodiments, the compound curve may include one or more concave curves and one or more convex curves. The convex shapes may be separated by a concave portion. The concave portion may be between the convex portion on the rigid housing and the convex portion on the electrodes. In some embodiments, the concave portion may correspond at least partially with a hinge, hinge region or area of reduced thickness between the body and a wing.
While described in the context of a heart monitor, the device improvements described herein are not so limited. The improvements described in this application may be applied to any of a wide variety of physiological data monitoring, recording and/or transmitting devices. The improved adhesion design features may also be applied to devices useful in the electronically controlled and/or time released delivery of pharmacological agents or blood testing, such as glucose monitors or other blood testing devices. As such, the description, characteristics and functionality of the components described herein may be modified as needed to include the specific components of a particular application such as electronics, antenna, power supplies or charging connections, data ports or connections for down loading or off loading information from the device, adding or offloading fluids from the device, monitoring or sensing elements such as electrodes, probes or sensors or any other component or components needed in the device specific function. In addition or alternatively, devices described herein may be used to detect, record, or transmit signals or information related to signals generated by a body including but not limited to one or more of ECG, EEG and/or EMG.
While the above embodiments disclose the invention with respect to a data channel for collecting a single physiological signal, it is contemplated that additional data channels can be include to collect additional data, for example, device motion, device flex or bed, heart rate and/or ambient electrical noise.
Various embodiments of a physiological monitoring device and methods for using it have been disclosed above. These various embodiments may be used alone or in combination, and various changes to individual features of the embodiments may be altered, without departing from the scope of the invention. For example, the order of various method steps may in some instances be changed, and/or one or more optional features may be added to or eliminated from a described device. Therefore, the description of the embodiments provided above should not be interpreted as unduly limiting the scope of the invention as it is set forth in the claims.
Various modifications to the implementations described in this disclosure may be made, and the generic principles defined herein may be applied to other implementations without departing from the spirit or scope of this disclosure. Thus, the claims are not intended to be limited to the implementations shown herein, but are to be accorded the widest scope consistent with this disclosure, the principles and the novel features disclosed herein.
Certain features that are described in this specification in the context of separate embodiments also can be implemented in combination in a single embodiment. Conversely, various features that are described in the context of a single embodiment also can be implemented in multiple embodiments separately or in any suitable subcombination. Moreover, although features may be described above as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination can in some cases be excised from the combination, and the claimed combination may be directed to a subcombination or variation of a subcombination.
Similarly, while operations are depicted in the drawings in a particular order, such operations need not be performed in the particular order shown or in sequential order, or that all illustrated operations be performed, to achieve desirable results. Further, the drawings may schematically depict one more example processes in the form of a flow diagram. However, other operations that are not depicted can be incorporated in the example processes that are schematically illustrated. For example, one or more additional operations can be performed before, after, simultaneously, or between any of the illustrated operations. Moreover, the separation of various system components in the embodiments described above should not be interpreted as requiring such separation in all embodiments. Additionally, other embodiments are within the scope of the following claims. In some cases, the actions recited in the claims can be performed in a different order and still achieve desirable results.
This application is a continuation of U.S. patent application Ser. No. 16/006,719, filed Jun. 12, 2018, which is a continuation of Ser. No. 14/162,656, filed, Jan. 23, 2014, which claims the benefit of U.S. Provisional Application No. 61/756,326, filed Jan. 24, 2013, entitled PHYSIOLOGICAL MONITORING DEVICE. The contents of the aforementioned applications are hereby incorporated by reference in their entireties as if fully set forth herein. The benefit of priority to the foregoing provisional application is claimed under the appropriate legal basis, including, without limitation, under 35 U.S.C. § 119(e).
Number | Name | Date | Kind |
---|---|---|---|
1497079 | Gullborg | Jun 1924 | A |
2179922 | Dana | Nov 1939 | A |
2201645 | Epner | May 1940 | A |
2311060 | Lurrain | Feb 1943 | A |
2500840 | Lyons | Mar 1950 | A |
3215136 | Holter et al. | Nov 1965 | A |
3547107 | Chapman et al. | Dec 1970 | A |
3870034 | James | Mar 1975 | A |
3882853 | Gofman | May 1975 | A |
3911906 | Reinhold | Oct 1975 | A |
4023312 | Stickney | May 1977 | A |
4027664 | Heavner, Jr. et al. | Jun 1977 | A |
4121573 | Crovella et al. | Oct 1978 | A |
4123785 | Cherry et al. | Oct 1978 | A |
4126126 | Bare | Nov 1978 | A |
4202139 | Hong et al. | May 1980 | A |
4274420 | Hymes | Jun 1981 | A |
4274429 | Tam et al. | Jun 1981 | A |
4286610 | Jones | Sep 1981 | A |
4333475 | Moreno et al. | Jun 1982 | A |
4361990 | Link | Dec 1982 | A |
4381792 | Busch | May 1983 | A |
4438767 | Nelson | Mar 1984 | A |
4459987 | Pangburn | Jul 1984 | A |
4535783 | Marangoni | Aug 1985 | A |
4537207 | Gilhaus | Aug 1985 | A |
4572187 | Schetrumpf | Feb 1986 | A |
4621465 | Pangburn | Nov 1986 | A |
4622979 | Katchis et al. | Nov 1986 | A |
4658826 | Weaver | Apr 1987 | A |
4712552 | Pangburn | Dec 1987 | A |
4736752 | Munck et al. | Apr 1988 | A |
4925453 | Kannankeril | May 1990 | A |
4938228 | Righter et al. | Jul 1990 | A |
4981141 | Segalowitz | Jan 1991 | A |
5003987 | Grinwald | Apr 1991 | A |
5027824 | Dougherty et al. | Jul 1991 | A |
5082851 | Appelbaum et al. | Jan 1992 | A |
5086778 | Mueller et al. | Feb 1992 | A |
5191891 | Righter | Mar 1993 | A |
5205295 | Del Mar et al. | Apr 1993 | A |
5226425 | Righter | Jul 1993 | A |
5228450 | Sellers | Jul 1993 | A |
5230119 | Woods et al. | Jul 1993 | A |
5289824 | Mills et al. | Mar 1994 | A |
5305746 | Fendrock | Apr 1994 | A |
5309909 | Gadsby | May 1994 | A |
5365935 | Righter et al. | Nov 1994 | A |
5458141 | Neil | Oct 1995 | A |
5483967 | Ohtake | Jan 1996 | A |
5489624 | Kantner et al. | Feb 1996 | A |
5511553 | Segalowitz | Apr 1996 | A |
5515858 | Myllymaki | May 1996 | A |
5536768 | Kantner et al. | Jul 1996 | A |
5581369 | Righter et al. | Dec 1996 | A |
5626140 | Feldman et al. | May 1997 | A |
5634468 | Platt et al. | Jun 1997 | A |
5645063 | Straka | Jul 1997 | A |
5645068 | Mezack et al. | Jul 1997 | A |
5730143 | Schwarzberg | Mar 1998 | A |
5749365 | Magill | May 1998 | A |
5749367 | Gamlyn et al. | May 1998 | A |
5771524 | Woods et al. | Jun 1998 | A |
5772604 | Langberg et al. | Jun 1998 | A |
5776072 | Hsu et al. | Jul 1998 | A |
5881743 | Nadel | Mar 1999 | A |
5931791 | Saltzstein et al. | Aug 1999 | A |
5941829 | Saltzstein et al. | Aug 1999 | A |
5957854 | Besson et al. | Sep 1999 | A |
5959529 | Kail | Sep 1999 | A |
6013007 | Root et al. | Jan 2000 | A |
6032060 | Carim | Feb 2000 | A |
6038469 | Karlsson et al. | Mar 2000 | A |
6044515 | Zygmont | Apr 2000 | A |
6093146 | Filangeri | Jul 2000 | A |
D429336 | Francis et al. | Aug 2000 | S |
6102856 | Groff et al. | Aug 2000 | A |
6117077 | Del Mar et al. | Sep 2000 | A |
6132371 | Dempsey et al. | Oct 2000 | A |
6134480 | Minogue | Oct 2000 | A |
6136008 | Becker et al. | Oct 2000 | A |
6161036 | Matsumura et al. | Dec 2000 | A |
6169915 | Krumbiegel et al. | Jan 2001 | B1 |
6178357 | Gliner et al. | Jan 2001 | B1 |
6200265 | Walsh et al. | Mar 2001 | B1 |
6225901 | Kail | May 2001 | B1 |
6232366 | Wang et al. | May 2001 | B1 |
6238338 | DeLuca et al. | May 2001 | B1 |
6248115 | Halk | Jun 2001 | B1 |
6287252 | Lugo | Sep 2001 | B1 |
6290707 | Street | Sep 2001 | B1 |
6315719 | Rode et al. | Nov 2001 | B1 |
6379237 | Gordon | Apr 2002 | B1 |
6385473 | Haines et al. | May 2002 | B1 |
6389308 | Shusterman | May 2002 | B1 |
6416471 | Kumar et al. | Jul 2002 | B1 |
6434410 | Cordero | Aug 2002 | B1 |
6441747 | Khair et al. | Aug 2002 | B1 |
6454708 | Ferguson et al. | Sep 2002 | B1 |
6456871 | Hsu et al. | Sep 2002 | B1 |
6456872 | Faisandier | Sep 2002 | B1 |
6464815 | Beaudry | Oct 2002 | B1 |
6493898 | Woods et al. | Dec 2002 | B1 |
6496705 | Ng et al. | Dec 2002 | B1 |
6510339 | Kovtun et al. | Jan 2003 | B2 |
6546285 | Owen et al. | Apr 2003 | B1 |
6564090 | Taha et al. | May 2003 | B2 |
6569095 | Eggers | May 2003 | B2 |
6577893 | Besson et al. | Jun 2003 | B1 |
6580942 | Willshire | Jun 2003 | B1 |
6585707 | Cabiri et al. | Jul 2003 | B2 |
6589170 | Flach et al. | Jul 2003 | B1 |
6589187 | Dimberger et al. | Jul 2003 | B1 |
6605046 | Del Mar et al. | Aug 2003 | B1 |
6615083 | Kupper | Sep 2003 | B2 |
6622035 | Merilainen | Sep 2003 | B1 |
6626865 | Prisell | Sep 2003 | B1 |
6656125 | Misczynski et al. | Dec 2003 | B2 |
6664893 | Eveland et al. | Dec 2003 | B1 |
6665385 | Rogers et al. | Dec 2003 | B2 |
6690959 | Thompson | Feb 2004 | B2 |
6694177 | Eggers et al. | Feb 2004 | B2 |
6701184 | Henkin | Mar 2004 | B2 |
6711427 | Ketelhohn | Mar 2004 | B1 |
6730028 | Eppstein | May 2004 | B2 |
6773396 | Flach et al. | Aug 2004 | B2 |
6775566 | Nissila | Aug 2004 | B2 |
6801137 | Eggers | Oct 2004 | B2 |
6801802 | Sitzman et al. | Oct 2004 | B2 |
6871089 | Korzinov et al. | Mar 2005 | B2 |
6871211 | Labounty et al. | Mar 2005 | B2 |
6875174 | Braun et al. | Apr 2005 | B2 |
6881191 | Oakley et al. | Apr 2005 | B2 |
6893396 | Schulze et al. | May 2005 | B2 |
6897788 | Khair et al. | May 2005 | B2 |
6904312 | Bardy | Jun 2005 | B2 |
6925324 | Shusterman | Aug 2005 | B2 |
6940403 | Kail | Sep 2005 | B2 |
6954163 | Toumazou et al. | Oct 2005 | B2 |
6957107 | Rogers et al. | Oct 2005 | B2 |
6987965 | Ng et al. | Jan 2006 | B2 |
7002468 | Eveland et al. | Feb 2006 | B2 |
7020508 | Stivoric et al. | Mar 2006 | B2 |
7024248 | Penner et al. | Apr 2006 | B2 |
7031770 | Collins et al. | Apr 2006 | B2 |
7072708 | Andresen et al. | Jul 2006 | B1 |
7072709 | Xue | Jul 2006 | B2 |
7076283 | Cho et al. | Jul 2006 | B2 |
7076287 | Rowlandson | Jul 2006 | B2 |
7076288 | Skinner | Jul 2006 | B2 |
7076289 | Sarkar et al. | Jul 2006 | B2 |
7079977 | Osorio et al. | Jul 2006 | B2 |
7082327 | Houben | Jul 2006 | B2 |
7089048 | Matsumura et al. | Aug 2006 | B2 |
7099715 | Korzinov et al. | Aug 2006 | B2 |
7117031 | Lohman et al. | Oct 2006 | B2 |
7120485 | Glass et al. | Oct 2006 | B2 |
7130396 | Rogers et al. | Oct 2006 | B2 |
7161484 | Tsoukalis | Jan 2007 | B2 |
7171166 | Ng et al. | Jan 2007 | B2 |
7179152 | Rhoades | Feb 2007 | B1 |
7186264 | Liddicoat et al. | Mar 2007 | B2 |
7193264 | Lande | Mar 2007 | B2 |
7194300 | Korzinov | Mar 2007 | B2 |
7206630 | Tarler | Apr 2007 | B1 |
7212850 | Prystowsky et al. | May 2007 | B2 |
7222054 | Geva | May 2007 | B2 |
7242318 | Harris | Jul 2007 | B2 |
7266361 | Burdett | Sep 2007 | B2 |
7316671 | Lastovich et al. | Jan 2008 | B2 |
7349947 | Slage et al. | Mar 2008 | B1 |
7354423 | Zelickson et al. | Apr 2008 | B2 |
7387607 | Holt et al. | Jun 2008 | B2 |
7444177 | Nazeri | Oct 2008 | B2 |
7477933 | Ueyama | Jan 2009 | B2 |
7478108 | Townsend et al. | Jan 2009 | B2 |
7481772 | Banet | Jan 2009 | B2 |
7482314 | Grimes et al. | Jan 2009 | B2 |
7502643 | Farringdon et al. | Mar 2009 | B2 |
7539533 | Tran | May 2009 | B2 |
7542878 | Nanikashvili | Jun 2009 | B2 |
7587237 | Korzinov et al. | Sep 2009 | B2 |
7630756 | Linker | Dec 2009 | B2 |
7632174 | Gringer et al. | Dec 2009 | B2 |
7672714 | Kuo et al. | Mar 2010 | B2 |
7715905 | Kurzweil et al. | May 2010 | B2 |
7729753 | Kremliovsky et al. | Jun 2010 | B2 |
7733224 | Tran | Jun 2010 | B2 |
D621048 | Severe et al. | Aug 2010 | S |
7815494 | Gringer et al. | Oct 2010 | B2 |
7841039 | Squire | Nov 2010 | B1 |
7889070 | Reeves et al. | Feb 2011 | B2 |
D634431 | Severe et al. | Mar 2011 | S |
7904133 | Gehman et al. | Mar 2011 | B2 |
7907956 | Uhlik | Mar 2011 | B2 |
7907996 | Prystowsky et al. | Mar 2011 | B2 |
7941207 | Korzinov | May 2011 | B2 |
7970450 | Kroecker et al. | Jun 2011 | B2 |
7996075 | Korzinov et al. | Aug 2011 | B2 |
7996187 | Nanikashvili et al. | Aug 2011 | B2 |
8002701 | Michael et al. | Aug 2011 | B2 |
8077042 | Peeters | Dec 2011 | B2 |
8103333 | Tran | Jan 2012 | B2 |
8108036 | Tran | Jan 2012 | B2 |
8116841 | Bly et al. | Feb 2012 | B2 |
8156945 | Hart | Apr 2012 | B2 |
D659836 | Bensch et al. | May 2012 | S |
8200319 | Pu et al. | Jun 2012 | B2 |
8214007 | Baker et al. | Jul 2012 | B2 |
8150502 | Kumar et al. | Aug 2012 | B2 |
8160682 | Kumar et al. | Aug 2012 | B2 |
8244335 | Kumar | Aug 2012 | B2 |
8249686 | Libbus et al. | Aug 2012 | B2 |
8261754 | Pitstick | Sep 2012 | B2 |
8265907 | Nanikashvili et al. | Sep 2012 | B2 |
RE43767 | Eggers et al. | Oct 2012 | E |
8280749 | Hsieh et al. | Oct 2012 | B2 |
8285356 | Bly et al. | Oct 2012 | B2 |
8290129 | Rogers et al. | Oct 2012 | B2 |
8290574 | Field et al. | Oct 2012 | B2 |
8301219 | Chen et al. | Oct 2012 | B2 |
8301236 | Baumann et al. | Oct 2012 | B2 |
8311604 | Rowlandson et al. | Nov 2012 | B2 |
8315687 | Cross et al. | Nov 2012 | B2 |
8315695 | Sebelius et al. | Nov 2012 | B2 |
8323188 | Tran | Dec 2012 | B2 |
8326394 | Rowlandson et al. | Dec 2012 | B2 |
8326407 | Linker | Dec 2012 | B2 |
8328718 | Tran | Dec 2012 | B2 |
8343116 | Ignon | Jan 2013 | B2 |
8374688 | Libbus et al. | Feb 2013 | B2 |
8386009 | Lindberg | Feb 2013 | B2 |
8406843 | Tiegs et al. | Mar 2013 | B2 |
8412317 | Mazar | Apr 2013 | B2 |
8425414 | Eveland | Apr 2013 | B2 |
8449471 | Tran | May 2013 | B2 |
8452356 | Vestel et al. | May 2013 | B2 |
8460189 | Libbus et al. | Jun 2013 | B2 |
8473039 | Michelson et al. | Jun 2013 | B2 |
8473047 | Chakravarthy et al. | Jun 2013 | B2 |
8478418 | Fahey | Jul 2013 | B2 |
8483809 | Kim et al. | Jul 2013 | B2 |
8500636 | Tran | Aug 2013 | B2 |
8515529 | Pu et al. | Aug 2013 | B2 |
8525673 | Tran | Sep 2013 | B2 |
8535223 | Corroy et al. | Sep 2013 | B2 |
8538503 | Kumar et al. | Sep 2013 | B2 |
8540731 | Kay | Sep 2013 | B2 |
8560046 | Kumar et al. | Oct 2013 | B2 |
8562527 | Braun et al. | Oct 2013 | B2 |
8571645 | Wu et al. | Oct 2013 | B2 |
8591430 | Amurthur et al. | Nov 2013 | B2 |
8594763 | Bibian | Nov 2013 | B1 |
8626262 | McGusty et al. | Jan 2014 | B2 |
8639319 | Hugh et al. | Jan 2014 | B2 |
8668643 | Kinast | Mar 2014 | B2 |
8684900 | Tran | Apr 2014 | B2 |
8684925 | Amurthur et al. | Apr 2014 | B2 |
8688189 | Shennib | Apr 2014 | B2 |
8688190 | Libbus et al. | Apr 2014 | B2 |
8688202 | Brockway et al. | Apr 2014 | B2 |
8718742 | Beck et al. | May 2014 | B2 |
8718752 | Libbus et al. | May 2014 | B2 |
8731632 | Sereboff et al. | May 2014 | B1 |
8738118 | Moon et al. | May 2014 | B2 |
8782308 | Vlach | Jul 2014 | B2 |
8790257 | Libbus et al. | Jul 2014 | B2 |
8795174 | Manicka et al. | Aug 2014 | B2 |
8818481 | Bly et al. | Aug 2014 | B2 |
8823490 | Libbus et al. | Sep 2014 | B2 |
8838218 | Khair | Sep 2014 | B2 |
8874185 | Sonnenborg | Oct 2014 | B2 |
8903477 | Berkner | Dec 2014 | B2 |
8903484 | Mazar | Dec 2014 | B2 |
8909330 | McCombie et al. | Dec 2014 | B2 |
8909832 | Vlach et al. | Dec 2014 | B2 |
8926509 | Magar et al. | Jan 2015 | B2 |
8945019 | Prystowsky et al. | Feb 2015 | B2 |
8954129 | Schlegel et al. | Feb 2015 | B1 |
8956293 | McCombie et al. | Feb 2015 | B2 |
8968195 | Tran | Mar 2015 | B2 |
8972000 | Manera | Mar 2015 | B2 |
8979755 | Szydlo-Moore et al. | Mar 2015 | B2 |
9014777 | Woo | Apr 2015 | B2 |
9015008 | Geva et al. | Apr 2015 | B2 |
9017255 | Raptis et al. | Apr 2015 | B2 |
9017256 | Gottesman | Apr 2015 | B2 |
9021161 | Vlach et al. | Apr 2015 | B2 |
9021165 | Vlach | Apr 2015 | B2 |
9026190 | Shenasa et al. | May 2015 | B2 |
9037223 | Oral et al. | May 2015 | B2 |
9044148 | Michelson et al. | Jun 2015 | B2 |
9084548 | Bouguerra | Jul 2015 | B2 |
9095274 | Fein et al. | Aug 2015 | B2 |
9101264 | Acquista | Aug 2015 | B2 |
9138144 | Geva | Sep 2015 | B2 |
9149228 | Kinast | Oct 2015 | B2 |
9173670 | Sepulveda et al. | Nov 2015 | B2 |
9179851 | Baumann et al. | Nov 2015 | B2 |
9211076 | Kim | Dec 2015 | B2 |
9226679 | Balda | Jan 2016 | B2 |
9241649 | Kumar et al. | Jan 2016 | B2 |
9241650 | Amirim | Jan 2016 | B2 |
9277864 | Yang et al. | Mar 2016 | B2 |
9282894 | Banet et al. | Mar 2016 | B2 |
9345414 | Bardy et al. | May 2016 | B1 |
9355215 | Vlach | May 2016 | B2 |
9357939 | Nosrati | Jun 2016 | B1 |
9364150 | Sebelius et al. | Jun 2016 | B2 |
9398853 | Nanikashvili | Jul 2016 | B2 |
9414786 | Brockway et al. | Aug 2016 | B1 |
9433367 | Felix et al. | Sep 2016 | B2 |
9439566 | Arne et al. | Sep 2016 | B2 |
9439599 | Thompson et al. | Sep 2016 | B2 |
9445719 | Libbus et al. | Sep 2016 | B2 |
9451890 | Gitlin et al. | Sep 2016 | B2 |
9451975 | Sepulveda et al. | Sep 2016 | B2 |
9474445 | Eveland | Oct 2016 | B2 |
9474461 | Fisher et al. | Oct 2016 | B2 |
D773056 | Vlach | Nov 2016 | S |
9492084 | Behar et al. | Nov 2016 | B2 |
9504423 | Bardy et al. | Nov 2016 | B1 |
9579020 | Libbus et al. | Feb 2017 | B2 |
9597004 | Hughes et al. | Mar 2017 | B2 |
9615793 | Solosko et al. | Apr 2017 | B2 |
9655518 | Lin | May 2017 | B2 |
9655538 | Felix et al. | May 2017 | B2 |
9706938 | Chakravarthy et al. | Jul 2017 | B2 |
9775534 | Korzinov et al. | Oct 2017 | B2 |
9782095 | Ylostalo et al. | Oct 2017 | B2 |
9839363 | Albert | Dec 2017 | B2 |
9901274 | Bishay et al. | Feb 2018 | B2 |
10271754 | Bahney | Apr 2019 | B2 |
20010056262 | Cabiri et al. | Dec 2001 | A1 |
20020067256 | Kail | Jun 2002 | A1 |
20020082491 | Nissila | Jun 2002 | A1 |
20020087167 | Winitsky | Jul 2002 | A1 |
20020180605 | Ozguz et al. | Dec 2002 | A1 |
20030069510 | Semler | Apr 2003 | A1 |
20030083559 | Thompson | May 2003 | A1 |
20030149349 | Jensen | Aug 2003 | A1 |
20030176795 | Harris et al. | Sep 2003 | A1 |
20030195408 | Hastings | Oct 2003 | A1 |
20030199811 | Sage, Jr. et al. | Oct 2003 | A1 |
20030212319 | Magill | Nov 2003 | A1 |
20040032957 | Mansy et al. | Feb 2004 | A1 |
20040068195 | Massicotte et al. | Apr 2004 | A1 |
20040077954 | Oakley et al. | Apr 2004 | A1 |
20040215091 | Lohman et al. | Oct 2004 | A1 |
20040236202 | Burton | Nov 2004 | A1 |
20040254587 | Park | Dec 2004 | A1 |
20040260189 | Eggers et al. | Dec 2004 | A1 |
20050096513 | Ozguz et al. | May 2005 | A1 |
20050101875 | Semler et al. | May 2005 | A1 |
20050118246 | Wong et al. | Jun 2005 | A1 |
20050119580 | Eveland | Jun 2005 | A1 |
20050165323 | Montgomery et al. | Jul 2005 | A1 |
20050204636 | Azar et al. | Sep 2005 | A1 |
20050277841 | Shennib | Dec 2005 | A1 |
20050280531 | Fadem et al. | Dec 2005 | A1 |
20060030781 | Shennib | Feb 2006 | A1 |
20060030782 | Shennib | Feb 2006 | A1 |
20060047215 | Newman et al. | Mar 2006 | A1 |
20060084883 | Linker | Apr 2006 | A1 |
20060142648 | Banet et al. | Jun 2006 | A1 |
20060142654 | Rytky | Jun 2006 | A1 |
20060149156 | Cochran et al. | Jul 2006 | A1 |
20060155173 | Anttila et al. | Jul 2006 | A1 |
20060155183 | Kroecker et al. | Jul 2006 | A1 |
20060155199 | Logier et al. | Jul 2006 | A1 |
20060155200 | Ng et al. | Jul 2006 | A1 |
20060161064 | Watrous et al. | Jul 2006 | A1 |
20060161065 | Elion | Jul 2006 | A1 |
20060161066 | Elion | Jul 2006 | A1 |
20060161067 | Elion | Jul 2006 | A1 |
20060161068 | Hastings et al. | Jul 2006 | A1 |
20060224072 | Shennib | Oct 2006 | A1 |
20060264767 | Shennib | Nov 2006 | A1 |
20070003695 | Tregub et al. | Jan 2007 | A1 |
20070010729 | Virtanen | Jan 2007 | A1 |
20070027388 | Chou | Feb 2007 | A1 |
20070088419 | Florina et al. | Apr 2007 | A1 |
20070156054 | Korzinov et al. | Jul 2007 | A1 |
20070225611 | Kumar et al. | Sep 2007 | A1 |
20070249946 | Kumar et al. | Oct 2007 | A1 |
20070255153 | Kumar et al. | Nov 2007 | A1 |
20070270678 | Fadem et al. | Nov 2007 | A1 |
20070293776 | Korzinov et al. | Dec 2007 | A1 |
20080039730 | Pu et al. | Feb 2008 | A1 |
20080091089 | Guillory et al. | Apr 2008 | A1 |
20080108890 | Teng et al. | May 2008 | A1 |
20080114232 | Gazit | May 2008 | A1 |
20080139953 | Baker | Jun 2008 | A1 |
20080275327 | Faarbaek et al. | Nov 2008 | A1 |
20080288026 | Cross et al. | Nov 2008 | A1 |
20090062670 | Sterling et al. | Mar 2009 | A1 |
20090073991 | Landrum et al. | Mar 2009 | A1 |
20090076336 | Mazar et al. | Mar 2009 | A1 |
20090076340 | Libbus et al. | Mar 2009 | A1 |
20090076341 | James et al. | Mar 2009 | A1 |
20090076342 | Amurthur et al. | Mar 2009 | A1 |
20090076343 | James et al. | Mar 2009 | A1 |
20090076344 | Libbus et al. | Mar 2009 | A1 |
20090076345 | Manicka et al. | Mar 2009 | A1 |
20090076346 | James et al. | Mar 2009 | A1 |
20090076349 | Libbus et al. | Mar 2009 | A1 |
20090076350 | Bly et al. | Mar 2009 | A1 |
20090076364 | Libbus et al. | Mar 2009 | A1 |
20090076397 | Libbus et al. | Mar 2009 | A1 |
20090076401 | Mazar et al. | Mar 2009 | A1 |
20090076559 | Libbus et al. | Mar 2009 | A1 |
20090182204 | Semler et al. | Jul 2009 | A1 |
20090253975 | Tiegs | Oct 2009 | A1 |
20090292194 | Libbus et al. | Nov 2009 | A1 |
20100022864 | Cordero | Jan 2010 | A1 |
20100042113 | Mah | Feb 2010 | A1 |
20100049006 | Magar et al. | Feb 2010 | A1 |
20100051039 | Ferrara | Mar 2010 | A1 |
20100056881 | Libbus et al. | Mar 2010 | A1 |
20100057056 | Gurtner | Mar 2010 | A1 |
20100081913 | Cross et al. | Apr 2010 | A1 |
20100145359 | Keller | Jun 2010 | A1 |
20100191310 | Bly | Jul 2010 | A1 |
20100234716 | Engel | Sep 2010 | A1 |
20100249625 | Lin | Sep 2010 | A1 |
20100268103 | McNamara et al. | Oct 2010 | A1 |
20100331711 | Krauss et al. | Dec 2010 | A1 |
20110021937 | Hugh et al. | Jan 2011 | A1 |
20110087083 | Poeze et al. | Apr 2011 | A1 |
20110144470 | Mazar et al. | Jun 2011 | A1 |
20110160601 | Wang et al. | Jun 2011 | A1 |
20110166468 | Prystowsky et al. | Jul 2011 | A1 |
20110190650 | McNair | Aug 2011 | A1 |
20110237922 | Parker, III | Sep 2011 | A1 |
20110306862 | Hayes-Gill | Dec 2011 | A1 |
20120029307 | Paquet et al. | Feb 2012 | A1 |
20120071730 | Romero | Mar 2012 | A1 |
20120071731 | Gottesman | Mar 2012 | A1 |
20120071743 | Todorov et al. | Mar 2012 | A1 |
20120083670 | Rotondo et al. | Apr 2012 | A1 |
20120088999 | Bishay et al. | Apr 2012 | A1 |
20120101396 | Solosko et al. | Apr 2012 | A1 |
20120108917 | Libbus et al. | May 2012 | A1 |
20120108920 | Bly et al. | May 2012 | A1 |
20120110226 | Vlach et al. | May 2012 | A1 |
20120110228 | Vlach et al. | May 2012 | A1 |
20120172676 | Penders et al. | Jul 2012 | A1 |
20120197150 | Cao et al. | Aug 2012 | A1 |
20120209102 | Ylotalo et al. | Aug 2012 | A1 |
20120215123 | Kumar et al. | Aug 2012 | A1 |
20120220835 | Chung | Aug 2012 | A1 |
20120259233 | Chan et al. | Oct 2012 | A1 |
20120271141 | Davies | Oct 2012 | A1 |
20120310070 | Kumar et al. | Dec 2012 | A1 |
20120323257 | Sutton | Dec 2012 | A1 |
20130046151 | Bsoul et al. | Feb 2013 | A1 |
20130085347 | Manicka et al. | Apr 2013 | A1 |
20130096395 | Katra et al. | Apr 2013 | A1 |
20130116533 | Lian et al. | May 2013 | A1 |
20130116585 | Bouguerra | May 2013 | A1 |
20130144146 | Linker | Jun 2013 | A1 |
20130150698 | Hsu et al. | Jun 2013 | A1 |
20130225938 | Vlach | Aug 2013 | A1 |
20130225967 | Esposito | Aug 2013 | A1 |
20130226018 | Kumar et al. | Aug 2013 | A1 |
20130245415 | Kumar et al. | Sep 2013 | A1 |
20130245472 | Eveland | Sep 2013 | A1 |
20130253285 | Bly et al. | Sep 2013 | A1 |
20130274584 | Brion et al. | Oct 2013 | A1 |
20130296680 | Linker | Nov 2013 | A1 |
20130300575 | Kurzweil et al. | Nov 2013 | A1 |
20130324868 | Kaib et al. | Dec 2013 | A1 |
20130331663 | Albert et al. | Dec 2013 | A1 |
20130331665 | Bly et al. | Dec 2013 | A1 |
20130338448 | Libbus et al. | Dec 2013 | A1 |
20140012154 | Mazar | Jan 2014 | A1 |
20140058280 | Chefles et al. | Feb 2014 | A1 |
20140094709 | Korzinov et al. | Apr 2014 | A1 |
20140100432 | Golda et al. | Apr 2014 | A1 |
20140171751 | Sankman et al. | Jun 2014 | A1 |
20140116825 | Kurzweil et al. | Jul 2014 | A1 |
20140206976 | Thompson et al. | Jul 2014 | A1 |
20140206977 | Bahney et al. | Jul 2014 | A1 |
20140275928 | Acquista et al. | Sep 2014 | A1 |
20140330136 | Manicka et al. | Nov 2014 | A1 |
20150022372 | Vosch | Jan 2015 | A1 |
20150057512 | Kapoor | Feb 2015 | A1 |
20150073252 | Mazar | Mar 2015 | A1 |
20150081959 | Vlach et al. | Mar 2015 | A1 |
20150082623 | Felix et al. | Mar 2015 | A1 |
20150087921 | Felix et al. | Mar 2015 | A1 |
20150087922 | Bardy et al. | Mar 2015 | A1 |
20150087923 | Bardy et al. | Mar 2015 | A1 |
20150087933 | Gibson et al. | Mar 2015 | A1 |
20150087948 | Bishay et al. | Mar 2015 | A1 |
20150087949 | Felix et al. | Mar 2015 | A1 |
20150087950 | Felix et al. | Mar 2015 | A1 |
20150087951 | Felix et al. | Mar 2015 | A1 |
20150088007 | Bardy et al. | Mar 2015 | A1 |
20150088020 | Dreisbach et al. | Mar 2015 | A1 |
20150094556 | Geva et al. | Apr 2015 | A1 |
20150173671 | Paalasmaa et al. | Jun 2015 | A1 |
20150238107 | Acquista et al. | Aug 2015 | A1 |
20150289814 | Magar et al. | Oct 2015 | A1 |
20150297134 | Albert et al. | Oct 2015 | A1 |
20150327781 | Hernandez-Silverira et al. | Nov 2015 | A1 |
20150351799 | Sepulveda et al. | Dec 2015 | A1 |
20150374244 | Yoo et al. | Dec 2015 | A1 |
20160022161 | Khair | Jan 2016 | A1 |
20160029906 | Tompkins et al. | Feb 2016 | A1 |
20160066808 | Hijazi | Mar 2016 | A1 |
20160113520 | Manera | Apr 2016 | A1 |
20160120433 | Hughes et al. | May 2016 | A1 |
20160120434 | Park et al. | May 2016 | A1 |
20160128597 | Lin et al. | May 2016 | A1 |
20160135746 | Kumar et al. | May 2016 | A1 |
20160157744 | Wu et al. | Jun 2016 | A1 |
20160166155 | Banet et al. | Jun 2016 | A1 |
20160192852 | Bozza et al. | Jul 2016 | A1 |
20160192855 | Geva et al. | Jul 2016 | A1 |
20160192856 | Lee | Jul 2016 | A1 |
20160198972 | Lee et al. | Jul 2016 | A1 |
20160232807 | Ghaffari et al. | Aug 2016 | A1 |
20160262619 | Marcus et al. | Sep 2016 | A1 |
20160287177 | Huppert et al. | Oct 2016 | A1 |
20160287207 | Xue | Oct 2016 | A1 |
20160296132 | Bojovic et al. | Oct 2016 | A1 |
20160302726 | Chang | Oct 2016 | A1 |
20160317048 | Chan et al. | Nov 2016 | A1 |
20160317057 | Li et al. | Nov 2016 | A1 |
20160367164 | Felix et al. | Dec 2016 | A1 |
20160374583 | Cerruti et al. | Dec 2016 | A1 |
20170065823 | Kaib et al. | Mar 2017 | A1 |
20170188872 | Hughes et al. | Jul 2017 | A1 |
Number | Date | Country |
---|---|---|
2011252998 | Aug 2015 | AU |
2014209376 | Jun 2017 | AU |
2752154 | Aug 2010 | CA |
2797980 | Nov 2011 | CA |
2898626 | Jul 2014 | CA |
2651203 | Sep 2017 | CA |
01782729 | May 2007 | EP |
1981402 | Oct 2008 | EP |
2262419 | Dec 2010 | EP |
2395911 | Dec 2011 | EP |
2568878 | Mar 2013 | EP |
2635179 | Sep 2013 | EP |
2635180 | Sep 2013 | EP |
2948050 | Dec 2015 | EP |
2983593 | Feb 2016 | EP |
3165161 | May 2017 | EP |
3212061 | Sep 2017 | EP |
2299038 | Sep 1996 | GB |
2348707 | Oct 2000 | GB |
08-317913 | Mar 1996 | JP |
2000-126145 | May 2000 | JP |
2001-057967 | Mar 2001 | JP |
2004-121360 | Apr 2004 | JP |
2007-045967 | Feb 2007 | JP |
2007-097822 | Apr 2007 | JP |
2007-296266 | Nov 2007 | JP |
2009-525816 | Jul 2009 | JP |
5203973 | Jun 2013 | JP |
5559425 | Jul 2014 | JP |
2014-236982 | Dec 2014 | JP |
2016-504159 | Feb 2016 | JP |
2017-136380 | Aug 2017 | JP |
6198849 | Sep 2017 | JP |
10-1513288 | Apr 2015 | KR |
WO 99023943 | May 1999 | WO |
WO 01016607 | Mar 2001 | WO |
WO 2004100785 | Nov 2004 | WO |
WO 2005025668 | Mar 2005 | WO |
WO 2005037946 | Apr 2005 | WO |
WO 2005084533 | Sep 2005 | WO |
WO 2006094513 | Sep 2006 | WO |
WO 2007049080 | Mar 2007 | WO |
WO 2007036748 | Apr 2007 | WO |
WO 2007063436 | Jun 2007 | WO |
WO 2007071180 | Jun 2007 | WO |
WO 2007072069 | Jun 2007 | WO |
WO 2007092543 | Aug 2007 | WO |
WO 2008005015 | Jan 2008 | WO |
WO 2008005016 | Jan 2008 | WO |
WO 2008057884 | May 2008 | WO |
WO 2008120154 | Oct 2008 | WO |
WO 2009074928 | Jun 2009 | WO |
WO 2009112976 | Sep 2009 | WO |
WO 2009112979 | Sep 2009 | WO |
WO 2009134826 | Nov 2009 | WO |
WO 2010104952 | Sep 2010 | WO |
WO 2010105203 | Sep 2010 | WO |
WO 2010093900 | Oct 2010 | WO |
WO 2011077097 | Jun 2011 | WO |
WO 2011143490 | Nov 2011 | WO |
WO 2011149755 | Dec 2011 | WO |
WO 2012009453 | Jan 2012 | WO |
WO 2012061509 | May 2012 | WO |
WO 2012061518 | May 2012 | WO |
WO 2012125425 | Sep 2012 | WO |
WO 2012160550 | Nov 2012 | WO |
WO 2014051563 | Apr 2014 | WO |
WO 2014116825 | Jul 2014 | WO |
WO 2014168841 | Oct 2014 | WO |
WO 2016070128 | May 2016 | WO |
WO 2016181321 | Nov 2016 | WO |
WO 2017039518 | Mar 2017 | WO |
WO 2017041014 | Mar 2017 | WO |
Entry |
---|
US 8,750,980 B2, 06/2014, Katra et al. (withdrawn) |
U.S. Appl. No. 15/005,854, filed Jan. 25, 2016, Kumar et al. |
3M Corporation, “3M Surgical Tapes—Choose the Correct Tape” quicksheet (2004). |
Del Mar et al.; The history of clinical holter monitoring; A.N.E.; vol. 10; No. 2; pp. 226-230; Apr. 2005. |
Enseleit et al.; Long-term continuous external electrocardiographic recording: a review; Eurospace; vol. 8; pp. 255-266; 2006. |
Hoefman et al.; Optimal duration of event recording for diagnosis of arrhythmias in patients with palpitations and light-headedness in the general practice; Family Practice; Dec. 7, 2006. |
International Search Report and Written Opinion for International Application No. PCT/US2014/012749 dated Mar. 21, 2014 in 20 pages. |
Kennedy et al.; The history, science, and innovation of holter technology; A.N.E.; vol. 11; No. 1; pp. 85-94; 2006. |
Mundt et al. “A Multiparameter Wearable Physiologic Monitoring System for Space and Terrestrial Applications” IEEE Transactions on Information Technology in Biomedicine, vol. 9, No. 3, pp. 382-384, Sep. 2005. |
Reiffel et al.; Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour holter monitors for arrhythmia detection; Am. J. Cardiology; vol. 95; pp. 1055-1059; May 1, 2005. |
Scapa Medical product listing and descriptions (2008) available at http://www.caapana.com/productlist.jsp and http://www.metplus.co.rs/pdf/prospekti/Samolepljivemedicinsketrake.pdf; retrieved via WayBack Machine Sep. 24, 2012. |
Ward et al.; Assessment of the diagnostic value of 24-hour ambulatory electrocardiographic monitoring; Biotelemetry Patient monitoring; vol. 7; 1980. |
Ziegler et al.; Comparison of continuous versus intermittent monitoring of atrial arrhythmias; Heart Rhythm; vol. 3; No. 12; pp. 1445-1452; Dec. 2006. |
Zimetbaum et al.; The evolving role of ambulatory arrhythmia monitoring in general clinic practice; Ann. Intern. Med.; vol. 130; pp. 846-8556; 1999. |
Zimetbaum et al.; Utility of patient-activated cardiac event recorders in general clinical practice; The Amer. J. of Cardiology; vol. 79; Feb. 1, 1997. |
Number | Date | Country | |
---|---|---|---|
20190246928 A1 | Aug 2019 | US |
Number | Date | Country | |
---|---|---|---|
61756326 | Jan 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16006719 | Jun 2018 | US |
Child | 16397651 | US | |
Parent | 14162656 | Jan 2014 | US |
Child | 16006719 | US |